EDITORIAL

Kyoto classification of gastritis: Advances and future perspectives in endoscopic diagnosis of gastritis

Toyoshima O, Nishizawa T

OPINION REVIEW

Current status of minimally invasive liver surgery for cancers

Morise Z

MINIREVIEWS

Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome

Sheng W, Ji G, Zhang L

ORIGINAL ARTICLE

Basic Study

Differential analysis of intestinal microbiota and metabolites in mice with dextran sulfate sodium-induced colitis


Salvia miltiorrhiza extract may exert an anti-obesity effect in rats with high-fat diet-induced obesity by modulating gut microbiome and lipid metabolism


Retrospective Study

Upper gastrointestinal endoscopic findings in celiac disease at diagnosis: A multicenter international retrospective study


SCIENTOMETRICS

Integrity of the editing and publishing process is the basis for improving an academic journal’s Impact Factor


CORRECTION

Correction to “MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promoter demethylation”

Zhang Z, Dai DQ
## ABOUT COVER
Editorial Board of *World Journal of Gastroenterology*, Yasuhito Tanaka, MD, PhD, Chief Professor, Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan. ytanaka@kumamoto-u.ac.jp

## AIMS AND SCOPE
The primary aim of *World Journal of Gastroenterology* (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

## INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

## RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yi-Xuan Cai; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

### NAME OF JOURNAL
*World Journal of Gastroenterology*

### ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

### LAUNCH DATE
October 1, 1995

### FREQUENCY
Weekly

### EDITORS-IN-CHIEF
Andrzej S Tarnawski

### EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/1007-9327/editorialboard.htm

### PUBLICATION DATE
November 21, 2022

### COPYRIGHT
© 2022 Baishideng Publishing Group Inc

### INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

### GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

### GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

### PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

### PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

### ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

### STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

### ONLINE SUBMISSION
https://www.f6publishing.com
Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome

Wei Sheng, Guang Ji, Li Zhang

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Pantelis AG, Greece; Villela-Nogueira CA, Brazil

Received: September 24, 2022
Peer-review started: September 24, 2022
First decision: October 18, 2022
Revised: October 20, 2022
Accepted: November 6, 2022
Article in press: November 6, 2022
Published online: November 21, 2022

Abstract
Nonalcoholic fatty liver disease (NAFLD) is strongly associated with sleep apnea syndrome (SAS). Many NAFLD patients have SAS, and obstructive sleep apnea hypopnea syndrome is also considered to be an independent risk factor for NAFLD, as it contributes to the progression of NAFLD via oxidative stress, lipid peroxidation, inflammation, and insulin resistance. This review aims to provide some recommendations for the management of NAFLD patients with SAS, including diet, exercise, weight loss, and continuous positive airway pressure. This review also highlights the importance of effective strategies in NAFLD prevention and treatment.

Key Words: Nonalcoholic fatty liver disease; Sleep apnea syndrome; Obesity; Obstructive sleep apnea hypopnea syndrome; Continuous positive airway pressure; Management

Core Tip: Nonalcoholic fatty liver disease (NAFLD) is strongly associated with sleep apnea syndrome (SAS). This minireview presents the relationship between NAFLD and SAS; addresses the role of obesity, insulin resistance, and oxidative stress, and emphasizes the management of NAFLD with SAS, which mainly includes lifestyle interventions and continuous positive airway pressure therapy. This review also highlights the importance of effective strategies in NAFLD prevention and treatment.

Citation: Sheng W, Ji G, Zhang L. Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome. World J Gastroenterol 2022; 28(43): 6099-6108
URL: https://www.wjgnet.com/1007-9327/full/v28/i43/6099.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i43.6099
INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis greater than 5% and excludes causes such as alcohol, viral infection and hereditary factors[1]. Due to numerous studies that have characterized the association of NAFLD with metabolic syndromes, such as obesity and type 2 diabetes (T2DM), an international consensus in 2020 proposed renaming NAFLD as metabolic-associated fatty liver disease (MAFLD)[2]. NAFLD can progress into nonalcoholic steatohepatitis (NASH) with or without fibrosis. Currently, there are two main hypotheses about the pathogenesis of NASH. One is the “two-hit” hypothesis proposed by James and Day[3] in 1998: The first strike is induced by insulin resistance and excessive accumulation of hepatic lipids, while oxidative stress and inflammation are considered to compose the second strike. As research in this field continues to advance, the “parallel multihits” hypothesis is thought to more accurately explain the complex mechanisms of NAFLD progression, which involves genetic and epigenetic factors, insulin resistance, endoplasmic reticulum stress, oxidative stress, and gut dysbiosis[3-5].

NAFLD patients are prone to sleep apnea syndrome (SAS), a common respiratory disease. It is estimated that nearly 1 billion adults aged 30-69 years worldwide have SAS. A real-world study of uncomplicated NAFLD patients in South Korea showed that during a median follow-up of 5.3 years, 1,351 patients (0.4%, total 3,343) were diagnosed with SAS; among patients with a fatty liver index > 31.0, SAS occurred in 0.8% of patients[6]. Based on the differences in their pathogenesis, SAS is broadly categorized into three types: Obstructive sleep apnea hypopnea syndrome (OSAHS), central SAS and mixed SAS. OSAHS is the most common type of SAS, and obesity is a strong risk factor for OSAHS. Approximately 40% of individuals with obesity are reported to have OSAHS, and 70% of OSAHS patients have obesity[7]. The etiology of OSAHS is complex, with the main causes including anatomical narrowing of the upper airway and local soft tissue collapse. Obesity exacerbates upper respiratory obstruction due to compression of the pharyngeal cavity and airway by neck fat[8-9]. It has been reported that central obesity and neck circumference thickening are significantly and positively associated with the apnea hypventilation index (AHI), and the AHI is also positively associated with insulin resistance[10]. In addition, the incidence of metabolic syndrome is elevated in patients with OSAHS compared to non-OSAHS; in particular, components of metabolic syndrome, such as T2DM, obesity, and dyslipidemia, are more strongly associated with OSAHS[11]. A German observational cohort study also found a higher incidence of hepatic steatosis in patients with moderate-to-severe OSAHS, and the assessment of a snoring index may help to identify the risks of associated liver disease in OSAHS patients[12]. More importantly, a previous meta-analysis found that OSAHS is associated with an increased risk of advanced fibrosis in NAFLD patients, independent of age, sex and body mass index (BMI)[13]. Another Italian observational cohort study suggested that evaluating the mean oxyhemoglobin percentage in obese patients with OSAHS is of great clinical value in identifying the risks of NAFLD progression[14]. However, because comorbidities coexist and are independently associated with systemic inflammation, it is very difficult to clarify the effects of OSAHS on the development and progression of NAFLD[15,16]. The exact mechanisms of NAFLD and SAS are still largely unknown, but some biological processes are considered to be integrated in NAFLD patients with SAS.

Hypoxia and oxidative stress

Lipid accumulation and subsequent oxidative stress in the liver are considered the initial causes of NAFLD progression and the development of NASH. The accumulation of free fatty acids in hepatocytes due to insulin resistance, increased de novo lipogenesis or excessive lipid uptake from dietary sources can disrupt the mitochondrial microstructure, leading to impaired fatty acid β-oxidation and the production of reactive oxygen species (ROS)[17,18]. Overwhelmed ROS can trigger oxidative stress, which is a stressful state involving an imbalance between oxidative and antioxidant actions, usually due to excess ROS interfering with endogenous antioxidant defense system[5]. Oxidative stress can exacerbate lipid accumulation in hepatocytes, disrupt the structure and function of mitochondria; activate Kupffer cells; and promote the release of inflammatory factors such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and IL-8, thereby exacerbating the inflammatory response of hepatocytes[19].

OSAHS is characterized by chronic intermittent hypoxia (CIH) that occurs at night, and prolonged CIH can lead to tissue hypoxia and promote oxidative stress, lipid peroxidation, and systemic inflammation. The disturbed lipid metabolism and excessive oxidative stress in the liver during NAFLD progression may further affect OSAHS. Accordingly, the combination of OSAHS aggravates hepatic impairment, promotes lipid metabolism disorder and increases insulin resistance in patients with NAFLD[20-22]. This was also demonstrated by the positive correlation between the severity of CIH in OSAHS patients and the severity of liver fibrosis measured by liver elastography[23]. Evidence from clinical investigations suggests an increased incidence of NAFLD in patients with OSAHS even in the absence of obesity or metabolic syndrome, while the severity of NAFLD is parallely associated with the severity of OSAHS in NAFLD patients with OSAHS[24]. More importantly, even in children with NAFLD, nocturnal hypoxia-induced oxidative stress promotes disease progression[25]. In addition, patients with OSAHS are at risk of hypoxemia and even hypercapnia due to the collapse of the pharynx.
during sleep, resulting in upper airway obstruction and airflow restriction, as well as respiratory distress and even interruption of breathing, leading to a decrease in oxygen saturation.

CIH, insulin resistance and disorders of lipid metabolism caused by OSAHS may exacerbate NAFLD in patients with obesity and lead to an increased risk of NASH and more serious diseases[26,27]. It has been reported that polymorphisms of proinflammatory cytokine genes including the highly sensitive C-reactive protein, IL-6 and leptin receptor genes are associated with increased risk of OSA and NAFLD in Asian Indians[28]. Moreover, Asian Indian subjects carrying the Gly972Arg polymorphism of insulin receptor substrate 1 are predisposed to developing OSA and NAFLD[29]. However, as mentioned previously, we do not yet fully understand the association between OSAHS and NAFLD. Current evidence suggests that OSAHS-related CIH triggers excessive lipolysis, manifesting as an increase in plasma free fatty acids[30,31]. Excessive free fatty acids lead to ectopic fat accumulation, insulin resistance, vascular dysfunction and dyslipidemia[32,33], which may be one of the mechanisms by which OSAHS promotes the progression of NAFLD[34]. Furthermore, CIH has also been hypothesized to promote oxidative stress through increased ROS production and angiogenesis, increased sympathetic activation with elevated blood pressure, and systemic and vascular inflammation with endothelial dysfunction[35].

**Diagnosis**

The diagnosis of NAFLD is primarily an exclusionary diagnosis, which is different from the diagnostic criteria for MAFLD. Secondary causes of hepatic steatosis and causes of liver complications due to other diseases must be excluded to make the diagnosis of NAFLD, including alcohol and drug use, hepatic viral infections and autoimmune liver diseases, Wilson’s disease and lipodystrophy[1,36,37]. Currently, the gold standard for NAFLD diagnosis (e.g., assessment of steatosis, steatohepatitis and the stage of liver fibrosis) remains liver biopsy and histological staining; however, it is inappropriate to routinely perform liver biopsy; because it is invasive and may pose a risk of complications, sampling errors and expert interpretation inconsistencies. Therefore, many noninvasive assessment and clinical scoring systems are used to diagnose and assess the degree of steatosis and fibrosis in patients with NAFLD. For example, abdominal ultrasonography, as a noninvasive and convenient method, and controlled attenuation parameter measurement based on transient elastography for ultrasonography attenuation are commonly used to detect the extent of liver steatosis[38]. Magnetic resonance imaging (MRI) is also applied in the noninvasive diagnosis and grading of NAFLD, and is considered to be efficient in quantifying liver fat, stiffness, and visceral adipose tissue[39]. The further developed MRI-proton density fat fraction and proton magnetic resonance spectroscopy are reported to be more concise technologies for NAFLD diagnosis[40]. Furthermore, hepatologists from the American Gastroenterology Association and Chronic Liver Disease Foundation summarized several commonly used noninvasive scores[41]. Among them, the fibrosis-4 index is the most widely studied and preferred simple noninvasive algorithm and it is used to evaluate the degree of liver fibrosis based on age and levels of platelet, aspartate aminotransferase (AST) and alanine aminotransferase (ALT)[42].

**Treatment**

The recommended treatment for NAFLD focuses on lifestyle interventions, including dieting, exercise, weight loss, and promotion of energy expenditure. In 2020, the Asia Pacific Association for the Study of the Liver proposed clinical practice guidelines for NAFLD. This guideline points out that conservative management of lifestyle changes remains the best choice for the treatment of NAFLD[37]. Notably, when NAFLD patients are combined with SBS, supplemental continuous positive airway pressure (CPAP) is the most appropriate approach. CPAP therapy has been reported to help improve sleep apnea and hypoventilation, as well as stabilize or delay the progression of NAFLD[24]. Inflammation, a hypoxic environment and oxidative stress are key pathogenic mechanisms in patients with NAFLD and OSAHS. Therefore, antioxidants such as vitamin E may be effective, and anti-obesity medications have also shown considerable potential in the treatment of NAFLD and OSAHS[43,44]. The glucagon-like peptide-1 receptor agonist, liraglutide and semaglutide may improve AHI and protect against NASH and obesity, especially in relation to T2DM[45,46]. Notably, liraglutide at a dose of 3 mg is well tolerated and is effective at improving NAFLD and OSAHS[47,48].

**Diet**

A reasonable dietary structure and appropriate dietary intake are beneficial for obesity, especially for NAFLD patients with OSAHS. Severely obese patients with NAFLD should strictly limit calorie intake, and if necessary, scientific recipes should be prescribed by nutritional experts to help alter the metabolic pattern. A Mediterranean diet is recommended for patients with NAFLD and NASH. Based on high amounts of monounsaturated fatty acids derived from olive oil, fruits, grains, whole grains and low-fat dairy products, the Mediterranean dietary pattern can reduce the incidence of metabolic syndrome, obesity, T2DM and cardiovascular disease, as well as certain cancers[49-51]. Remarkably, the Mediterranean diet may potentially counteract the inflammation and oxidative stress that occur in OSAHS and improve upper-airway neuromuscular control and muscle force-generating capacity[32]. In an interdisciplinary weight loss and lifestyle intervention trial, participants who adhered to the Mediterranean diet...
demonstrated greater weight loss as well as more significant improvement in OSAHS[53].

In addition, the diversity of foods should be increased for patients with NAFLD, and the foods need to be enriched for antioxidants and high-quality proteins, which can contribute to NAFLD and OSAHS improvement. However, NAFLD patients should reduce the consumption of specific foods, including red meat and overprocessed foods[54]. Moderate coffee consumption is allowed for NAFLD patients, but the intake of alcohol, fructose and sugar-containing drinks should be avoided because alcohol or sugar consumption can increase lipid synthesis, visceral fat accumulation and insulin resistance, and increase the risk of liver fibrosis in patients with NAFLD.

**Exercise**

Exercise is beneficial for NAFLD and SAS. Previous studies have shown that sedentary and reduced physical activity is associated with the progression of NAFLD and the development of moderate to severe OSAHS[55,56]. There is growing evidence showing that aerobic exercise training is beneficial for patients with SAS[57]. Active physical activity may reduce body weight, improve blood circulation, contribute to sleep quality and address excessive daytime sleepiness. Therefore, regular exercise facilitates weight loss and improves NAFLD and associated complications[58,59]. The recommended minimum level of exercise is 5 d per week (> 30 min each day) of moderate intensity aerobic exercise or 3 d per week (> 20 min each day) of vigorous exercise.

**Metabolic bariatric surgery**

For NAFLD patients with severe obesity, weight loss is very difficult due to their large weight base and may require metabolic bariatric surgery (MBS) intervention. Over the past few decades, MBS has evolved from the simple gastric volume-limiting procedure laparoscopic adjustable gastric banding to surgical options with hormonal effects, including vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB), both of which induce appetite changes by modulating intestinal and central hormones, thereby reducing food consumption and increasing satiety[60]. Usually, MBS is the most effective treatment for obesity and often results in dramatic improvements in glycemic control, insulin resistance and NAFLD[61,62].

SAS is also one of the comorbidities with the greatest response rate to MBS. The 6th IFSO Global Registry Report shows that MBS leads to a reduction of SAS ranging from 58%-65%, depending on the type of operation (LSG, RYGB, OAGB). Evidence from clinical studies has confirmed the efficacy of MBS for patients with obesity and OSAHS[63,64]. A retrospective study comparing the effect of VSG and RYGB on weight loss and their comorbidity remission also showed that both MBSs are effective in improving OSAHS symptoms[65]. Most surprisingly, in a study observing the effect of VSG in patients with a BMI ≥ 50 kg/m², complete remission was observed in all 13 patients with comorbid OSAHS[66]. MBS can effectively control sleep apnea and nocturnal hypoxia, as well as hepatic steatosis and fibrosis [67,68]. More importantly, the severity of OSAHS determines the risk of NAFLD before MBS, and after surgery, it also determines the improvement of NAFLD[67].

**CPAP**

CPAP is the first-line recommendation for the treatment of OSAHS. For NAFLD patients with OSAHS, early intervention is even more important. Additionally, for obesity and OSAHS patients scheduled for MBS, guidelines recommend preemptive CPAP for at least 4 wk[69]. CPAP acts in multiple pathways to prevent airway collapse, reduce pharyngeal edema and upper airway resistance, increase the action of upper airway opening muscles through vagal reflexes, and restore chemoreceptor sensitivity and respiratory center drive. CPAP treatment has been reported to significantly reduce sleep apnea and hyperventilation in patients with OSAHS, improve quality of life; reduce daytime sleepiness, and decrease the occurrence of hypertension, diabetes, cardiovascular and cerebrovascular complications [70]. This may be because CPAP treatment reduces markers of oxidative stress and thus improves metabolic syndrome[71]. In addition, a randomized controlled trial showed that patients with OSAHS had increased markers of liver injury and atherogenic risk[72], whereas CPAP treatment helped stabilize or delay the progression of NAFLD and demonstrated improvements in metabolic and cardiovascular function[24]. A meta-analysis of 192 obesity patients combined with OSAHS showed a significant reduction in serum AST and ALT levels after CPAP treatment for 3 mo[73]. Another meta-analysis of six randomized controlled trials involving 699 subjects also showed that CPAP treatment reduces total cholesterol and triacylglycerol levels[74]. More importantly, CPAP treatment of patients with OSAHS significantly reduces serum inflammatory markers, including CRP and TNF-α[75]. More interestingly, in another randomized controlled trial, Sundaram et al[76] found that CPAP treatment reverses the parameters of liver injury, reduces oxidative stress in children with NAFLD and can also be used to predict NAFLD progression in obese children with OSAHS.

Although these reports point to a beneficial effect of CPAP on NAFLD-associated parameters[73,74,77,78], short-term (usually 4-12 wk) CPAP treatment may not be as effective[72,79,80]. The most significant result of CPAP treatment is a case report published in 2018 that reported the reversal of NAFLD and the normalization of liver enzymes and the associated lipidome in a patient with both NAFLD and severe OSAHS after 6 years of treatment[81]. In addition, long-term follow-up data based
Figure 1 Management of nonalcoholic fatty liver disease with sleep apnea syndrome. Healthy lifestyle management remains the current first-line recommendation for nonalcoholic fatty liver disease (NAFLD) with sleep apnea syndrome (SAS), including diet, exercise, and weight loss. For patients with obesity and type 2 diabetes, drug intervention should also include anti-obesity medications and insulin-sensitizing drugs. Metabolic bariatric surgery can be considered when lifestyle changes and medical interventions are not effective. In addition, continuous positive airway pressure therapy may improve both intermittent hypoxia and liver injury in patients with NAFLD and SAS. MBS: Metabolic bariatric surgery; CPAP: Continuous positive airway pressure; IR: Insulin resistance; LAGB: Laparoscopic adjustable gastric banding; VSG: Vertical sleeve gastrectomy; RYGB: Roux-en-Y gastric bypass; SAS: Sleep apnea syndrome; NAFLD: Nonalcoholic fatty liver disease.

on a Taiwanese population also showed a lower cumulative incidence of NAFLD and cirrhosis in CPAP-treated patients than in nontreated patients[82]. Therefore, the beneficial effects of short-term CPAP therapy on OSAHS and NAFLD may be elusive, and although long-term and effective CPAP treatment can show significant improvements in both OSAHS and NAFLD, most patients are not amenable to long-term oral and nasal mask therapy. In addition, CPAP therapy is not yet commonly used due to the high cost of the device.

CONCLUSION

Obesity is a high-risk factor for NAFLD and SAS. Most patients living with obesity and metabolic syndrome are prone to SAS, and the severity of disease in patients with SAS is significantly associated with NAFLD progression. It is important to note that, even in nonobese patients, there is a relationship between NAFLD progression and SAS severity. SAS is usually one of the complications of NAFLD. However, at present, we can only confirm that lipid disorders, hypoxia, oxidative stress, and inflammation are involved, and a deeper understanding of the pathogenesis remains unclear. More in-depth studies are needed to elucidate the causal relationship between them. More importantly, an understanding of the pathogenesis will help us to develop more individualized treatment plans.

Collectively, healthy lifestyle management remains the most important strategy for the treatment of NAFLD, including diet, exercise and weight loss. Furthermore, the use of antioxidants such as vitamin E and the insulin-sensitizing drug pioglitazone is also necessary. It needs to be emphasized again that timely CPAP intervention is also important for NAFLD patients with SAS. We have summarized our recommendations for NAFLD combined with SAS management in Figure 1, and the improvements in SAS and NAFLD after intervention with lifestyle measures, medications and MBS are summarized in Table 1.
Table 1 Effects of current strategies on nonalcoholic fatty liver disease with sleep apnea syndrome

<table>
<thead>
<tr>
<th>Category</th>
<th>Effects</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mediterranean diet</td>
<td>Inhibition of inflammation and oxidative stress that occur in OSAHS and improvement of upper-airway neuromuscular control and muscle force-generating capacity</td>
<td>[51]</td>
</tr>
<tr>
<td>Dietary behavior change, moderate-intensity aerobic exercise, sleep hygiene, and tobacco and alcohol avoidance</td>
<td>Increases in adherence to the Mediterranean diet Reduced AHI and oxygen desaturation index Increased sleep quality Decrease of body weight, fat mass, visceral adipose tissue, and neck, chest, and waist circumferences</td>
<td>[52]</td>
</tr>
<tr>
<td>Aerobic exercise training</td>
<td>Reduced body weight improved blood circulation, better sleep quality and less daytime sleepiness</td>
<td>[56-58]</td>
</tr>
<tr>
<td>Phentermine plus extended-release topiramate</td>
<td>Significant improvements in overnight oxygen saturation and reduction in blood pressure</td>
<td>[42]</td>
</tr>
<tr>
<td>Liraglutide and semaglutide</td>
<td>Histological resolution of NASH and improved metabolic control Decreased AHI, body weight, SBP and HbA1c</td>
<td>[43-48]</td>
</tr>
<tr>
<td>VSG or other MBS</td>
<td>Reduced AHI</td>
<td>[62-64]</td>
</tr>
<tr>
<td>VSG</td>
<td>100% remission rate in patients with OSAHS who also underwent hiatal hernia repair</td>
<td>[65]</td>
</tr>
<tr>
<td>MBS</td>
<td>Improved sleep apnea and nocturnal hypoxia, as well as liver steatosis and fibrosis</td>
<td>[66]</td>
</tr>
</tbody>
</table>

OSAHS: Obstructive sleep apnea hypopnea syndrome; AHI: Apnea hypoventilation index; NASH: Nonalcoholic steatohepatitis; SBP: Systolic blood pressure; HbA1c: Glycated hemoglobin; MBS: Metabolic bariatric surgery; VSG: Vertical sleeve gastrectomy.

FOOTNOTES

Author contributions: Sheng W performed the literature review and wrote the manuscript; Zhang L and Ji G conceptualized the idea, and critically reviewed and revised the manuscript; and all authors have read and approved the final manuscript.

Supported by the Project of Shanghai Hospital Development Center, No. SHDC2020CR4044.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Wei Sheng 0000-0002-8428-5204; Guang Ji 0000-0003-0842-3676; Li Zhang 0000-0002-5338-6096.

S-Editor: Wang JJ
L-Editor: A
P-Editor: Wang JJ

REFERENCES


Sheng W et al. Management of NAFLD and SAS

29 Bhatt SP, Guleria R. Association of IRS1 (Gly972Arg) and IRS2 (Gly1057Asp) genes polymorphisms with OA and NAFLD in Asian Indians. PLoS One 2021; 16: e0245408 [PMID: 3449768 DOI: 10.1371/journal.pone.0245408]


36 European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]


72 Xie X, Pan L, Ren D, Du C, Guo Y. Effects of continuous positive airway pressure therapy on systemic inflammation in


79 Kohler M, Pepperell JC, Davies RJ, Stradling JR. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration 2009; 78: 141-146 [PMID: 18984944 DOI: 10.1159/000170785]


81 Bajantri B, Lvovsky D. A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy. Gastroenterology Res 2018; 11: 252-259 [PMID: 29915639 DOI: 10.14740/gr1033w]
